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Brief Definit ive Report
HIV-1 gains access into the body mainly during 
sexual intercourse, by crossing epithelial barriers 
that cover mucosal surfaces of both the male and 
female genital tracts. In stratified epithelia, such as 
those of the foreskin and vagina, Langerhans cells 
(LCs) are among the first cells that capture HIV-1 
as a result of their close proximity to the mucosal 
surface and their ability to bind the HIV-1 enve-
lope glycoprotein subunit gp120 via their specific 
C-type lectin langerin. Although at low viral 
concentrations HIV-1 binding to langerin leads 
to viral internalization and degradation, at higher 
viral concentrations, the protective effect of lan-
gerin is inhibited (de Witte et al., 2007), per-
mitting transfer of internalized intact virions to 
T cells across LC–T cell conjugates (Ganor et al., 
2010; Zhou et al., 2011). Such viral transfer in-
duces extensive replication of the virus in T cells. 
The natural endogenous host factors that control 
this process are unknown.
Genital epithelia are innervated by periph-
eral neurons secreting different neuropeptides. 
Among these is the 37-aa neuropeptide calcito-
nin gene–related peptide (CGRP; also termed 
CGRP), which is produced by alternative 
splicing of the calcitonin gene (Rosenfeld et al., 
1983) and induces potent vasodilatation (Brain 
et al., 1985). The CGRP receptor is an assembly 
of the seven-transmembrane domain G-protein–
coupled receptor calcitonin receptor–like recep-
tor (CRLR), an associated single transmembrane 
domain protein termed receptor activity modi-
fying protein 1 (RAMP1), and an additional 
intracellular protein termed receptor compo-
nent protein (RCP) required for functionality 
(Walker et al., 2010). CGRP might also acti-
vate receptors for the related peptides adreno-
medullin (i.e., coexpression of CRLR with 
RAMP2-3) and amylin (i.e., coexpression of 
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Upon its mucosal entry, human immunodeficiency virus type 1 (HIV-1) is internalized by 
Langerhans cells (LCs) in stratified epithelia and transferred locally to T cells. In such epithe-
lia, LCs are in direct contact with peripheral neurons secreting calcitonin gene–related pep-
tide (CGRP). Although CGRP has immunomodulatory effects on LC functions, its potential 
influence on the interactions between LCs and HIV-1 is unknown. We show that CGRP acts 
via its receptor expressed by LCs and interferes with multiple steps of LC-mediated HIV-1 
transmission. CGRP increases langerin expression, decreases selected integrins, and activates 
NF-B, resulting in decreased HIV-1 intracellular content, limited formation of LC–T cell 
conjugates, and elevated secretion of the CCR5-binding chemokine CCL3/MIP-1. These 
mechanisms cooperate to efficiently inhibit HIV-1 transfer from LCs to T cells and T cell 
infection. In vivo, HIV-1 infection decreases CGRP plasma levels in both vaginally SHIV-
challenged macaques and HIV-1–infected individuals. CGRP plasma levels return to baseline 
after highly active antiretroviral therapy. Our results reveal a novel path by which a periph-
eral neuropeptide acts at the molecular and cellular levels to limit mucosal HIV-1 transmis-
sion and suggest that CGRP receptor agonists might be used therapeutically against HIV-1.
© 2013 Ganor et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Figure 1. CGRP inhibits HIV-1 transfer from LCs to T cells. (A and B) MDLCs were left untreated or pretreated for 24 h with 100 nM CGRP. The cells 
were then pulsed with 101–103 (A) or 103 (B) TCID50 HIV-1 and co-cultured with autologous CD4+ T cells for 1 wk. Untreated MDLCs were also co-cultured 
with T cells in the presence of AZT or cultured alone (A, open bar). In A, HIV-1 replication was measured in the culture supernatants by p24 ELISA, and 
results represent mean ± SEM ng/ml p24 from duplicate wells of a representative experiment of n = 9; *, P < 0.0001; ANOVA. In B, the cells were col-
lected at the end of the co-culture period, stained with CD3-APC (surface) and p24-PE (intracellular) mAbs, and examined by flow cytometry; shown are 
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cells derived from n = 5 experiments of 7.4 ± 0.7% and 0.3 ± 
0.1%, respectively; P < 0.0001). In contrast, when the cells 
were double-stained for surface CD1a and intracellular p24, a 
significantly lower proportion of CD1a+ cells was p24+ (1.3 ± 
0.2%, n = 5; P < 0.0001 vs. CD3+p24+ cells), confirming the 
inefficient replication of HIV-1 in MDLCs. These results 
show that our experimental settings are appropriate for the 
investigation of HIV-1 transfer from LCs to T cells.
MDLCs were next pretreated with CGRP at a concen-
tration range previously found effective in suppressing LC-
mediated antigen presentation (0.1–100 nM; Hosoi et al., 1993), 
before the HIV-1 pulse, and HIV-1 transfer to T cells and T cell 
infection were measured as described above. Because the effi-
ciency of viral transfer varied when using MDLCs and T cells 
prepared from different human individuals, the calculated 
p24 levels in the co-culture supernatants using untreated 
MDLCs were normalized to 100% for each experiment, allow-
ing for direct comparison. CGRP pretreatment of MDLCs 
resulted in a dose- and time-dependent inhibition of HIV-1 
transfer to T cells, reaching maximal inhibition of 73.3 ± 
4.2% after pretreatment with 100 nM CGRP for 24 h (Fig. 1, 
A–C). Similar inhibition was observed when MDLCs were 
pulsed with another clade B/R5 HIV-1 molecular clone (ADA; 
not depicted). The inhibitory effect of CGRP was not a result 
of increased mortality, as the viability of both untreated and 
CGRP-treated MDLCs at the end of the co-culture period 
was similar (90% as evaluated by trypan blue exclusion).
Although CGRP modulates several T cell functions (e.g., 
adhesion and cytokine secretion), HIV-1 transfer was not 
affected when T cells were pretreated with CGRP and 
then co-cultured with untreated but HIV-1–pulsed MDLCs 
(Fig. 1 C). Previous observations also showed that CGRP in-
hibits antigen presentation to T cells when LCs, but not T cells, 
are pretreated with CGRP (Hosoi et al., 1993).
The inhibitory effect of CGRP was mediated specifically 
via the CGRP receptor, as the CGRP receptor antagonist 
CGRP8–37 abrogated this effect (Fig. 1 C), whereas the linear 
receptor agonist Cys(Acm)2,7 that acts on related amylin recep-
tors, which are also activated by CGRP (Poyner et al., 2002), 
was ineffective (Fig. 1 C). In agreement with a potential role 
of this receptor, RT-PCR showed that MDLCs expressed 
the calcitonin receptor with RAMP1-3), which mediate 
the previously described CGRP type 2 receptor phenotype 
(Poyner et al., 2002).
CGRP appears as a possible modulator of LC function. 
CGRP neurons are in direct contact with LCs in the skin, and 
early observations showed that CGRP inhibits LC antigen 
presentation to T cells (Hosoi et al., 1993). A later study dem-
onstrated that although CGRP inhibits LC-mediated Th1 anti-
gen presentation and cytokine secretion, it enhanced that of 
Th2 (Ding et al., 2008). Herein, we hypothesized that CGRP 
could also interfere with the interactions between LCs and 
HIV-1. As peripheral neurons are lost upon tissue sampling, 
such potential interactions were never studied at the mucosal 
level. Our results show that CGRP affects multiple molecular 
and cellular events in LCs, resulting in efficient inhibition of 
HIV-1 transfer from LCs to T cells and T cell infection.
RESULTS AND DISCUSSION
HIV-1 transfer from LCs to T cells
To measure the transfer of HIV-1 from LCs to T cells, we 
prepared blood monocyte-derived LCs (MDLCs) and pulsed 
the cells with the HIV-1 molecular clone JRCSF (clade B, 
R5 tropism). MDLCs were then co-cultured with autolo-
gous CD4+ T cells, and HIV-1 replication was measured in 
the co-culture supernatants 1 wk later by p24 ELISA. In line 
with previous observations (de Witte et al., 2007), MDLCs 
inefficiently transferred HIV-1 to T cells at low viral concen-
trations (Fig. 1 A), corresponding to 101 and 102 tissue cul-
ture infectious doses (TCID50). In contrast, at a high HIV-1 
concentration of 103 TCID50, MDLCs efficiently transferred 
the virus to T cells, a process which was significantly abrogated 
by the antiretroviral drug azidothymidine (AZT; Fig. 1 A). 
MDLCs pulsed with 103 TCID50 HIV-1 and cultured alone 
without T cells inefficiently replicated the virus (Fig. 1 A). 
To confirm these results using a direct read-out for viral rep-
lication, the cells were collected at the end of the co-culture 
period, double-stained for surface CD3 and intracellular 
p24, and examined by flow cytometry. A clear population of 
CD3+p24+ infected T cells was detected, which was com-
pletely absent when AZT was included during the co-culture 
period (Fig. 1 B; mean ± SEM percentages of CD3+p24+ 
representative FACS plots, with numbers indicating the mean ± SEM percentages of CD3+p24+ infected T cells of n = 5 experiments. (C) MDLCs were left 
untreated or pretreated, as indicated, for 3–24 h with 0.1–100 nM CGRP, 1,000 nM CGRP8–37 (added alone or 10 min before addition of CGRP), or 100 nM 
Cys(Acm)2,7. The cells were then pulsed with 103 TCID50 HIV-1 and co-cultured with autologous CD4+ T cells for 1 wk. In some experiments, T cells were 
pretreated with CGRP and then co-cultured with untreated but HIV-1–pulsed MDLCs (gray bar). HIV-1 replication was measured in the co-culture super-
natants by p24 ELISA, and results represent mean ± SEM from n = 9 experiments of HIV-1 transfer normalized against untreated cells serving as the 
100% set point; numbers represent percentage of HIV-1 transfer inhibition; *, P = 0.0220 and 0.0003 and P < 0.0001 and 0.0001 for 1 nM/3 h, 10 nM/3 h, 
100 nM/3 h, and 100 nM/24 h CGRP-treated versus untreated MDLCs, respectively. (D) RT-PCR images for CRLR, RAMP1-3, and RCP in MDLCs from three 
individuals with total human brain (HB) RNA serving as positive control. (E and F) MULCs were left untreated or pretreated for 24 h with 0.1–100 nM 
CGRP, culture supernatants of TT cells containing 70 nM (high) or 4 nM (low) CGRP (F, striped bars), 1,000 nM CGRP8–37 (added alone or 10 min before 
addition of CGRP), or 100 nM Cys(Acm)2,7, as indicated. The cells were then pulsed with 103 TCID50 HIV-1 and co-cultured with CD4+ T cells for 1 wk.  
HIV-1 replication was measured in the co-culture supernatants by p24 ELISA, and results of n = 5 experiments are presented as in A and B, respectively; 
p24 level of untreated MULCs cultured alone was 12.0 ± 0.2 ng/ml; *, P = 0.0315 for MULCs pretreated with 100 nM CGRP versus untreated MULCs (E);  
*, P = 0.0008 and 0.0338 for MULCs pretreated with 100 nM CGRP and high CGRP versus untreated MULCs, respectively (F). (G) RT-PCR images for CRLR, 
RAMP1-3, and RCP in MULCs (representative of n = 3 experiments).
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shown by RT-PCR (Fig. 1 G). Expression of CRLR and 
RAMP1 was lower in MULCs relative to MDLCs. Such 
reduced expression of CRLR and RAMP1, the later neces-
sary for the targeting of CRLR to the plasma membrane (Walker 
et al., 2010), might provide a possible explanation for the 
lower ability of CGRP to inhibit HIV-1 transfer to T cells 
from MULCs versus MDLCs.
Langerin expression and HIV-1 replication
MDLCs differentiated from blood monocytes not only ex-
press the LC markers CD1a, CD11c, and langerin, but also 
DC-SIGN. As DC-SIGN mediates HIV-1 trans-infection 
of T cells (Geijtenbeek et al., 2000), we investigated its 
possible role in CGRP-mediated inhibition of HIV-1 trans-
fer. Hence, we prepared in parallel MDLCs and monocyte-
derived DCs (MDDCs) using monocytes from the same 
human individuals and examined the effect of CGRP on 
DC-SIGN expression on MDLCs and HIV-1 transfer from 
MDDCs to T cells. CGRP pretreatment (100 nM, 24 h) had 
no effect on CD1a, CD11c, and DG-SIGN expression on 
MDLCs (Fig. 2 A) and did not affect HIV-1 transfer from 
CRLR, RAMP1, and RCP, the components forming the 
CGRP receptor (Fig. 1 D). In contrast, MDLCs did not express 
RAMP2 and RAMP3 (Fig. 1 D).
LCs were also prepared from the human CD34+ acute 
myeloid leukemia cell line MUTZ-3 (MUTZ-3–derived LCs 
[MULCs]). At a high HIV-1 concentration of 103 TCID50, 
MULCs efficiently transferred the virus to T cells; CGRP 
inhibited such viral transfer, reaching maximal inhibition of 
26.2 ± 3.6% after pretreatment of MULCs with 100 nM 
CGRP for 24 h (Fig. 1, E and F). Endogenous CGRP pro-
duced by the thyroid carcinoma cell line TT (Schifter, 1997) 
exerted an inhibitory effect comparable with that of the syn-
thetic CGRP used above. Hence, pretreatment of MULCs 
for 24 h with TT culture supernatants containing 70 nM en-
dogenous CGRP resulted in 24.7% inhibition of HIV-1 
transfer to T cells, whereas pretreatment with 4 nM endoge-
nous CGRP did not (Fig. 1 F). The inhibitory effects of both 
synthetic and endogenous CGRP were mediated via the CGRP 
receptor, as they were abrogated by CGRP8–37, whereas 
Cys(Acm)2,7 was ineffective (Fig. 1 F). MULCs expressed 
CRLR, RAMP1, RAMP2, and RCP, but not RAMP3, as 
Figure 2. CGRP increases langerin surface expression and decreases HIV-1 replication. (A) Representative FACS histograms showing surface  
expression of CD1a, CD11c, DC-SIGN, and langerin in untreated and CGRP-pretreated MDLCs or LCs derived from inner foreskin versus matched isotype 
controls. Numbers represent mean ± SEM ratios of the MFI for langerin expression (MFI langerin/MFI isotype) derived from n = 15 (MDLCs) or 5 (foreskin 
LCs) experiments; P < 0.0001 and 0.0352 for CGRP-treated versus untreated LCs, respectively. (B) MDDCs were left untreated or pretreated for 24 h with 
100 nM CGRP, pulsed with HIV-1 at 103 TCID50, and either co-cultured with autologous CD4+ T cells or cultured alone (open bar) for 1 wk. HIV-1 replica-
tion was measured in the culture supernatants by p24 ELISA. Results represent mean ± SEM ng/ml p24 from n = 4 experiments; *, P = 0.0361 MDDCs 
alone versus MDDCs + T cells. (C–E) MDLCs were pretreated with CGRP (100 nM, 24 h) alone or after addition of 1,000 nM CGRP8–37 and pulsed with HIV-1  
at 103 TCID50. MDLCs were then either incubated with trypsin and lysed immediately, and HIV-1 was measured in the cell lysates (C), or cultured alone in 
the absence of CD4+ T cells, and HIV-1 was measured in the culture supernatants 1 wk later (D). Untreated MDLCs were also pulsed with HIV-1 at 103 
TCID50 in the presence of dynasore or cytochalasin D and co-cultured with autologous CD4+ T cells, and HIV-1 was measured in the co-culture super-
natants 1 wk later (E). Results represent mean ± SEM LC intracellular content of HIV-1 (C; pg p24), HIV-1 replication (D; ng/ml p24), or normalized HIV-1 
transfer (E; percentage) derived from n = 7, 4, and 3 independent experiments, respectively; numbers in E represent percent inhibition; *, P = 0.0054 and 
0.0006 for 100 nM versus no CGRP (C and D); *, P = 0.0145 and 0.0102 for dynasore and cytochalasin D versus untreated MDLCs, respectively (E).
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In contrast, CGRP pretreatment (100 nM, 24 h) signifi-
cantly increased by approximately twofold langerin expres-
sion on MDLCs (Fig. 2 A). To substantiate these observations 
MDDCs to T cells (Fig. 2 B). These results suggest that 
CGRP-mediated inhibition of HIV-1 transfer does not in-
volve DC-SIGN.
Figure 3. CGRP decreases LC adhesive potential, 
LC–T cell conjugate formation, and T cell infection 
and increases CCL3/MIP-1 secretion. (A) Represen-
tative FACS histograms showing surface expression of 
the indicated integrins in untreated or CGRP-pretreated 
(100 nM, 24 h) MDLCs versus matched isotype controls. 
Numbers represent mean ± SEM (n = 7) MFI ratios for 
integrin expression (MFI integrin/MFI isotype) for each 
surface marker; P = 0.0279 (CD29), 0.0198 (CD49e), and 
0.0275 (CD50) for CGRP-treated versus untreated 
MDLCs, respectively. The graph represents mean ± SEM 
of the decrease in expression (percentage) of CD29, 
CD49e, and CD50 after 24-h pretreatment with CGRP 
alone, 1,000 nM CGRP8–37 + 100 nM CGRP, or 100 nM 
Cys(Acm)2,7; *, P = 0.0163, 0.0086, and 0.0252 for CD29, 
CD49e, and CD50 versus untreated MDLCs, respectively. 
(B) Mean ± SEM (n = 5) percentages of untreated or 
CGRP-pretreated (100 nM, 3 h) MDLCs adhering in vitro 
to fibronectin-coated plates; number represents per-
cent decrease; *, P = 0.0265, 100 nM versus no CGRP. 
(C) Representative FACS profiles showing the percent-
ages of conjugates forming in vitro between CD4+ T cells 
(CellTracker orange labeled) and MDLCs (CellTracker 
green labeled). (top) MDLCs were either left untreated 
or CGRP pretreated (100 nM, 24 h). (bottom) Untreated 
MDLCs were incubated with CD4+ T cells in the presence 
of control, ICAM-3, or ICAM-1 Ab. Numbers represent 
the mean ± SEM (n = 5) percentage of double-positive 
conjugates; P = 0.0103, 0.0097, and 0.0320 for 100 nM 
CGRP, ICAM-3 Ab, and ICAM-1 Ab versus no CGRP, 
respectively. (D) Inner foreskin explants were either left 
untreated (no CGRP) or CGRP pretreated (100 nM 
CGRP) for 24 h and exposed for 4 h to either nonin-
fected or HIV-1–infected cells. Shown are representa-
tive FACS profiles with numbers representing the mean ±  
SEM (n = 3) percentages within the entire cell suspen-
sions of either CD3+CD1a+ high FSC LC–T cell conjugates 
(top, epidermis) or CD3+p24+ cells (bottom, dermis). 
Cells were first gated on CD3+ cells (R1 gates, left pro-
files; insets show staining with matched isotype con-
trols). (E and F) HIV-1 transfer experiments in the 
presence of control Ab or neutralizing Ab to CCL3  
(E; n = 3) or the PKA inhibitor H89 or the NF-B inhibitors 
BAY117082 and MG132 (F; n = 4). Results are pre-
sented as in Fig. 1. *, P = 0.0148, 0.0441, and 0.0229 for 
pretreatment with CGRP alone, CGRP + control Ab, and 
CGRP + 100 ng/ml CCL3 Ab versus untreated MDLCs, 
respectively (E); *, P < 0.0001 and P = 0.0004 and 
0.0009 for pretreatment with CGRP alone and in the 
presence of 1 µM of either H89 or BAY117082 versus 
untreated MDLCs, respectively (F).
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in relevant mucosal in vivo conditions, we evaluated the effect 
of CGRP on langerin expression in human foreskin mucosa. 
Using our newly developed ex vivo system, we recently re-
ported that exposure of human adult inner foreskin explants 
to HIV-1–infected cells results in HIV-1 internalization by 
LCs, which then transfer HIV-1 to T cells across LC–T cell 
conjugates (Ganor et al., 2010; Zhou et al., 2011). Here, simi-
lar inner foreskin explants were used to evaluate the effect of 
CGRP pretreatment (100 nM, 24 h) on langerin expression 
in epidermal single-cell suspensions. In agreement with our 
aforementioned in vitro observations, CGRP pretreatment 
also increased langerin expression on inner foreskin epider-
mal LCs (Fig. 2 A).
Depending on the HIV-1 dose, the interaction between 
HIV-1 and LCs involves multiple steps, including binding, 
internalization, degradation, and/or transfer. To investigate 
the potential impact of CGRP on this complex interaction, 
untreated or CGRP-pretreated MDLCs were first pulsed with 
HIV-1. The cells were then incubated with trypsin to remove 
surface-bound virus as we previously reported (Magérus-
Chatinet et al., 2007) and lysed, and the intracellular amounts 
of HIV-1 were measured in the cell lysates. CGRP pretreat-
ment resulted in a decrease in the intracellular HIV-1 content 
(Fig. 2 C). In addition, although HIV-1 replication in MDLCs 
is inefficient (Fig. 1 A), CGRP significantly reduced this low 
viral replication, an effect which was abrogated by CGRP8–37 
(Fig. 2 D). To further sustain these observations, either dyna-
sore (a dynamin inhibitor which prevents the scission of 
clathrin-coated pits which play a role in langerin recycling) or 
cytochalasin D (an actin polymerization inhibitor, acting as an 
endocytosis blocker which increases langerin surface expres-
sion; Mc Dermott et al., 2002) was added to untreated MDLCs 
during the viral pulse period. Both dynasore and cytochalasin 
D increased langerin surface levels (mean ± SEM fluorescent 
intensities [MFIs] from n = 4 experiments of 42.8 ± 6.2 
[untreated], 91.6 ± 16.3 [dynasore treated], and 108.9 ± 8.0 
[cytochalasin D treated] MDLCs; P = 0.0090 and P < 0.0001 vs. 
untreated MDLCs, respectively; Student’s t test) and inhib-
ited HIV-1 transfer to T cells in a magnitude similar to that of 
100 nM CGRP (Fig. 2 E). Hence, CGRP (as well as dynasore 
and cytochalasin D) increases langerin expression, decreases 
HIV-1 content and replication in MDLCs, and inhibits HIV-1 
transfer from LCs to T cells. These findings might suggest that 
by increasing langerin cell surface expression, CGRP enhances 
HIV-1 degradation. Yet, these findings do not rule out the pos-
sibility that CGRP might rather decrease HIV-1 uptake, result-
ing in lower intracellular HIV-1 content and replication. Future 
studies are needed now to resolve these open questions.
LC–T cell mucosal conjugate formation and T cell infection
HIV-1 transfer from LCs to T cells takes place across the infec-
tious viral synapse. This transient adhesive LC–T cell cellular 
conjugate is maintained by specific interactions of various ad-
hesion molecules on the two cell types, such as that between 
CD11a (LFA-1) on T cells and CD54 (ICAM-1) and especially 
CD50 (ICAM-3) on LCs (Griffiths et al., 1995). To investigate 
whether CGRP-mediated inhibition of HIV-1 transfer involves 
modulation of LCs’ adhesive potential, we evaluated the sur-
face expression levels of several integrins. CGRP pretreatment 
(100 nM, 24 h) of MDLCs decreased the expression of CD29 
(1), CD49e (5), and CD50 (ICAM-3), while not affecting 
that of CD18 (2), CD49f (6), and CD54 (ICAM-1) inte-
grins (Fig. 3 A). The inhibitory effect of CGRP was medi-
ated via the CGRP receptor, as it was abrogated by CGRP8–37, 
whereas Cys(Acm)2,7 was ineffective (Fig. 3 A). Consequently, 
CGRP pretreatment decreased the percentage of MDLCs ad-
hering to fibronectin-coated plates (Fig. 3 B), a process which 
is mediated by the 15 integrin. CGRP also decreased the 
percentage of conjugates forming between fluorescently labeled 
MDLCs and T cells, as did antibodies (Abs) to either ICAM-3 
or ICAM-1 (Fig. 3 C). Similar results were obtained when con-
jugate formation was evaluated with MULCs (not depicted).
Our recent study demonstrated that exposure of human 
adult inner foreskin explants to HIV-1–infected cells results 
in increased formation of LC–T cell conjugates (Zhou et al., 
2011). However, upon mucosal tissue sampling, peripheral 
neurons are sectioned and the role of endogenous neuropep-
tides could not be studied. Therefore, we further evaluated 
the effect of CGRP on LC–T cell conjugate formation and 
T cell infection in these explants. Direct HIV-1 transfer exper-
iments, as described above, could not be performed with LCs 
from foreskin explants because of limiting cell numbers. In 
agreement with our recent findings (Zhou et al., 2011), expo-
sure of inner foreskin explants to HIV-1–infected cells in-
creased the percentage of LC–T cell conjugates compared 
with exposure to noninfected cells (Fig. 3 D, top; mean ± 
SEM fold percentage LC–T cell conjugates [n = 3] of 2.1 ± 
0.1, P = 0.0019; Student’s t test). Moreover, a small but sig-
nificant proportion of T cells was infected in these explants 
(Fig. 3 D, bottom; P = 0.0110 for HIV-1–infected vs. non-
infected cells [n = 3]; Student’s t test). In contrast, CGRP 
pretreatment (100 nM, 24 h) abrogated the increase in LC–T 
cell conjugate formation and T cell infection, mediated by 
HIV-1–infected cells. Both remained similar to that in ex-
plants exposed to noninfected cells (Fig. 3 D).
Of note, the effective concentration of 100 nM CGRP 
used herein in foreskin explants seems to be within its normal 
range in the skin (e.g., 10–23 pmol CGRP per gram of mouse 
skin [Ahmed et al., 1998], which translates to 28–65 nM 
CGRP, considering that skin contains around 35% water). 
Together, these results suggest that both in vitro and ex vivo, 
CGRP restricts T cell infection by decreasing LC–T cell 
conjugate formation.
CCL3/MIP-1 secretion
CGRP decreases Th1 and increases Th2 cytokine/chemo-
kine secretion by LCs (Ding et al., 2008). Of special interest 
in the context of HIV-1 are the CCR5-binding chemokines 
CCL3/MIP-1, CCL4/MIP-1, and CCL5/RANTES, which 
block HIV-1 infection by binding the HIV-1 coreceptor 
CCR5 on target cells. To investigate whether CGRP-mediated 
inhibition of HIV-1 transfer might be related to altered secretion 
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CGRP plasma levels
HIV-1 infection is associated in vivo with loss of cutane-
ous innervation and reduced epidermal nerve fiber density 
(McCarthy et al., 1995; Zhou et al., 2007). As sensory periph-
eral nerves innervating the skin/foreskin are reactive for CGRP 
(Hosoi et al., 1993), we hypothesized that their loss expected 
to occur upon HIV-1 infection in vivo will result in reduc-
tion of CGRP levels. We tested this hypothesis by measuring 
CGRP in plasma of HIV-1–infected individuals, as foreskin 
tissues from such patients are difficult to obtain. Although 
the normal plasma level of CGRP is low (picomolar range) 
and seems insufficient to operate at the mucosal level (nano-
molar range), it serves as a clinical peripheral marker for the 
deregulation of CGRP in several pathological conditions 
(e.g., increased in patients with migraine and decreased in 
patients with hypertension). We found that CGRP levels 
were significantly decreased in a group of HIV-1–infected 
patients compared with healthy individuals (Fig. 4 A). In an 
additional group of HIV-1–infected patients receiving highly 
active antiretroviral therapy (HAART), CGRP levels were nor-
malized back to baseline levels (Fig. 4 A). To determine whether 
the reduced levels of plasma CGRP in HIV-1–infected indi-
viduals result directly from the presence of the incoming virus 
early in infection, we also measured CGRP levels in female 
macaques that were vaginally challenged with SHIV to mimic 
viral transmission during sexual intercourse. These animals 
were described in our recent study, which demonstrated the 
protective efficacy of a gp41-based vaccine active at mucosal 
sites in protecting against repeated vaginal SHIV challenge 
(Bomsel et al., 2011). Hence, CGRP plasma levels were mea-
sured comparatively in the placebo-vaccinated animals before 
SHIV challenge and at several later time points at which all 
animals were infected (see Bomsel et al. [2011] for details re-
garding the immunization protocol, SHIV doses delivered, 
and viral loads). This analysis showed that CGRP levels 
gradually decreased after repeated vaginal SHIV challenges 
(Fig. 4 B). These results suggest that HIV-1/SHIV infection 
is associated with reduced circulating levels of CGRP in vivo.
We show herein that CGRP efficiently inhibits HIV-1 trans-
fer from LCs to T cells, limits HIV-1 infection of T cells, and 
is decreased in HIV-1–infected patients and SHIV-challenged 
of these chemokines, we measured their levels comparatively 
in culture supernatants of CGRP-treated versus untreated 
MDLCs and MULCs that were pulsed with HIV-1 and co-
cultured for 1 wk with T cells, as described above. These experi-
ments revealed that pretreatment with 100 nM CGRP resulted 
in increased CCL3/MIP-1 secretion but did not affect that 
of CCL4/MIP-1 and CCL5/RANTES (mean ± SEM fold 
secretion from n = 4 experiments of 1.69 ± 0.1 [P = 0.0003; 
Student’s t test], 0.9 ± 0.2, and 1.2 ± 0.2, respectively). To test 
whether CGRP-induced elevation of CCL3/MIP-1 secre-
tion contributes to the inhibition of HIV-1 transfer, we added 
a CCL3/MIP-1 neutralizing Ab during the co-culture period. 
The CCL3/MIP-1 neutralizing Ab abrogated CGRP-
mediated inhibition of HIV-1 transfer from MDLCs to T cells 
in a dose-dependent manner, whereas a control Ab had no sig-
nificant effect (Fig. 3 E). Both the control and CCL3/MIP-
1 neutralizing Abs had no effect on HIV-1 transfer from 
untreated MDLCs to T cells (not depicted). In addition, we also 
included a CCR5-neutralizing Ab (clone 2D7) in other HIV-1 
transfer experiments and found that this Ab completely inhibits 
viral transfer (not depicted). Together, these results clearly show 
that blocking CCR5 on T cells by either CCL3/MIP-1 or a 
neutralizing Ab impairs HIV-1 transfer.
As transcriptional up-regulation of the CCL3/MIP-1 gene 
is mediated by NF-B, we hypothesized that CGRP-mediated 
increase in CCL3/MIP-1 secretion results from NF-B activa-
tion. To test this assumption, we treated MDLCs with 100 nM 
CGRP alone or in the presence of the pharmacological NF-B 
inhibitors BAY117082 or MG132 and evaluated viral transfer to 
T cells as before. MDLCs were also treated with CGRP in the 
presence of the PKA inhibitor H89, as CGRP also induces PKA 
activation upon binding to its receptor (Walker et al., 2010). 
BAY117082 and MG132 abrogated the inhibition of HIV-1 
transfer (Fig. 3 F). This abrogation was accompanied by a reduc-
tion in CGRP-induced elevation in CCL3/MIP-1 secretion 
that returned to baseline levels (mean ± SEM fold secretion from 
n = 4 experiments of 1.0 ± 0.1 for the highest concentration of 
BAY117082). In contrast, H89 had no effect on HIV-1 transfer 
from MDLCs to T cells (Fig. 3 F). These results demonstrate that 
the anti–HIV-1 activity of CGRP in LCs involves specifically 
the NF-B, rather than PKA, signaling cascade.
Figure 4. CGRP plasma levels are decreased in HIV-
infected individuals and SHIV-challenged animals. (A) CGRP 
levels were measured in the plasma of 14 noninfected con-
trol individuals, 14 HIV-1–infected individuals, and 10 HIV-1– 
infected individuals under HAART. Horizontal lines denote 
the means ± SEM; *, P = 0.0001 HIV-1 infected versus nonin-
fected; *, P = 0.0176 HIV-1 infected + HAART versus HIV-1 
infected. (B) Mean ± SEM CGRP levels in the plasma of six 
female macaques before (prechallenge) and at days 46, 72, 
100, and 128 after repeated SHIV challenge. *, P = 0.0133 
and 0.0017 for days 100 and 128 after SHIV challenge versus 
prechallenge, respectively.
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MATERIALS AND METHODS
Cells. PBMCs from healthy donors were separated from whole blood by a 
standard Ficoll gradient. CD14+ monocytes and CD4+ T cells were obtained 
from PBMCs by negative magnetic selection (STEMCELL Technologies) 
according to the manufacturer’s instructions. MUTZ-3 cells were obtained 
from the German Collection of Microorganisms and Cell Cultures (DSMZ), 
and TT cells were obtained from the ATCC. Both cell lines were main-
tained according to the supplier’s guidelines. MDLCs, MDDCs, and MULCs 
were prepared and maintained as described previously (Geissmann et al., 
1998; Masterson et al., 2002); mean ± SEM percentage of MDLCs express-
ing surface langerin (see below) was 13.6 ± 4.1% (n = 24).
HIV-1 transfer. 105 MDLCs, 105 MDDCs, and 2.5 × 104 MULCs were 
pretreated with CGRP, CGRP8–37 (Sigma-Aldrich), Cys(Acm)2,7 (Bachem), 
or CGRP-containing TT culture supernatants in a 96-well round-bottom 
plate (200 µl/well final), washed, and pulsed with HIV-1 JRCSF (National 
Institutes of Health [NIH]) for 2 h (0.1–10 ng corresponding to 101–103 
TCID50, prepared as described previously [Ganor et al., 2010; Zhou et al., 
2011]). In some experiments, dynasore or cytochalasin D (Sigma-Aldrich) 
was added during the pulse period at the indicated concentrations. The 
cells were then incubated with trypsin for 10 min and lysed with NP-40 or 
washed again and incubated with T cells (3 × 105; autologous for MDLCs). 
In other experiments, AZT (Sigma-Aldrich), normal goat IgG, neutralizing 
CCL3/MIP-1 goat Ab (R&D Systems), the NF-B inhibitors BAY117082 
and MG132 (Santa Cruz Biotechnology, Inc.), or the PKA inhibitor H89 
(Tocris Bioscience) was included. HIV-1 was measured by p24 ELISA 
(Innotest; Innogenetics) immediately in the cell lysates or in the co-culture 
supernatants 1 wk later. The cells were also collected at the end of the co-
culture period, double labeled for surface CD3 or CD1a and intracellular 
p24 expression, and examined by flow cytometry as we recently described 
(Ganor et al., 2013).
RT-PCR. Expression of components comprising the CGRP and related 
receptors was evaluated by RT-PCR as described previously (CRLR and 
RAMP2 [Sams and Jansen-Olesen, 1998], RAMP1 and RAMP3 [Bailey 
and Hay, 2006], and RCP [Moreno et al., 2002]); total human brain RNA 
(Takara Bio Inc.) served as positive control.
Flow cytometry. MDLCs (105/well) were stained with APC-conjugated 
mouse anti–human CD1a, CD11c, and DC-SIGN mAbs (BD), PE-conjugated 
mouse anti–human langerin mAb (clone DCGM4; Beckman Coulter), or 
10 µg/ml of the indicated primary mouse anti–human integrin mAbs 
(ImmunoTools) followed by 1:50 dilution of a secondary FITC-conjugated 
anti–mouse IgG (Jackson ImmunoResearch Laboratories, Inc.). Cells stained 
with matched isotype mAbs served as negative control. Each step was per-
formed for 30 min on ice at 50 µl/well. Fluorescent profiles were recorded 
using a FACSCalibur (BD), and results were analyzed using the CellQuest 
Pro software (BD).
Adhesive potential and inner foreskin explants. Adhesion in vitro to 
fibronectin (Sigma-Aldrich)-coated plates (5,000 MDLCs/well) was per-
formed as we described previously (Ganor et al., 2007). For conjugate for-
mation in vitro, 105 MDLCs were labeled according to the manufacturer’s 
instructions with CellTracker green (Molecular Probes), pretreated with 
CGRP, washed, and incubated with 3 × 105 CellTracker orange–labeled 
T cells for 1 h. Untreated and labeled MDLCs were also incubated with labeled 
T cells in the presence of mouse anti–human CD50 (ICAM-3) or CD54 
(ICAM-1) mAbs (ImmunoTools) at 20 µg/ml. The percentage of double-
positive conjugates was measured by flow cytometry. Inner foreskin explants 
were prepared, inoculated with HIV-1–infected PBMCs, and processed for 
flow cytometry as we recently described (Zhou et al., 2011).
Ethical approval and human study population. All human participants 
were recruited at the Department of Infectious Diseases of the San Raffaele 
Scientific Institute, Milan, Italy. The institutional review board and the local 
animals. CGRP exerts its anti–HIV-1 activities by a combi-
nation of several different mechanisms, rather than by a single 
distinct one, which cooperate together. As such, CGRP pos-
sesses some of the properties that characterize cellular HIV-1 
restriction factors (Blanco-Melo et al., 2012): CGRP acts 
autonomously and exhibits antiviral activity in vitro, it employs 
unique mechanisms to inhibit viral transfer, and its activity 
might be counteracted in the presence of HIV-1. Yet, in con-
trast to cellular HIV-1 restriction factors, CGRP exerts its anti-
viral potential indirectly. We suggest, therefore, that CGRP 
could be considered a novel indirect HIV-1–limiting factor, 
which acts at the extracellular rather than intracellular level.
Activation of the CGRP receptor results in Gs-mediated 
activation of adenylate cyclase, with a subsequent increase in 
cAMP and activation of PKA (Walker et al., 2010), which 
results in relaxation of smooth muscle cells and vasodilatation. 
Interestingly, a previous study showed that although CGRP 
increases cAMP production in LCs, such increase alone was 
not sufficient for inhibiting LC-mediated antigen presentation 
(Asahina et al., 1995). A later study showed that the inhibition 
of LC-mediated antigen presentation by CGRP involves the 
NF-B pathway (Ding et al., 2007). These findings suggest that 
different signaling pathways contribute to CGRP-induced 
vasodilatation in smooth muscle cells versus immunosuppression 
in LCs. Accordingly, our results show that the NF-B pathway 
activated by CGRP mediates HIV-1 transfer inhibition.
CGRP is secreted from peripheral neurons that innervate 
essentially all organs in the body, including mucosal epithelia. 
These CGRP neurons are in direct contact with LCs in the 
skin (Hosoi et al., 1993), as well as with macrophages in the 
skin and lymphoid organs. CGRP inhibits antigen presenta-
tion and cytokine secretion not only in LCs but also in mac-
rophages (Torii et al., 1997). We can therefore speculate that 
the HIV-1 inhibitory activity of CGRP may be relevant also 
to later time points during HIV-1 infection after LC migra-
tion and viral dissemination in such organs. Additionally, CGRP 
would potentially control HIV-1 spread within the nervous 
system itself, where macrophages (as well as microglia) are the 
principal cells targeted by HIV-1.
CGRP is involved in migraine pathophysiology, in which 
its plasma levels are increased. Clinical trials have clearly 
demonstrated the efficacy of CGRP receptor antagonists for 
the treatment of migraine (Olesen et al., 2004). Based on our 
results herein, we suggest that enhancing CGRP receptor acti-
vation in LCs might provide novel means for limiting HIV-1 
spread. Hence, novel CGRP receptor agonists, active espe-
cially at mucosal epithelia at targeting LCs, might represent a 
completely new class of anti–HIV-1 molecules.
Our study not only reveals a novel immunosuppressive ef-
fect of CGRP on LC function and its mechanisms of action, 
but also provides for the first time the evidence that the nervous 
system can restrict “at a distance” the early events of HIV-1 
transmission at the mucosal level. Whether CGRP serves as a 
natural barrier to HIV-1 transmission and contributes to the 
rather low degree of infection during sexual intercourse re-
mains an open question.
 o
n
 Septem
ber 26, 2014
jem.rupress.org
D
ow
nloaded from
 
Published September 30, 2013
JEM Vol. 210, No. 11 2169
Br ief Definit ive Repor t
de Witte, L., A. Nabatov, M. Pion, D. Fluitsma, M.A. de Jong, T. de Gruijl, 
V. Piguet, Y. van Kooyk, and T.B. Geijtenbeek. 2007. Langerin is a 
natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 
13:367–371. http://dx.doi.org/10.1038/nm1541
Ding, W., J.A. Wagner, and R.D. Granstein. 2007. CGRP, PACAP, and 
VIP modulate Langerhans cell function by inhibiting NF-kappaB acti-
vation. J. Invest. Dermatol. 127:2357–2367. http://dx.doi.org/10.1038/ 
sj.jid.5700858
Ding, W., L.L. Stohl, J.A. Wagner, and R.D. Granstein. 2008. Calcitonin 
gene-related peptide biases Langerhans cells toward Th2-type immunity. 
J. Immunol. 181:6020–6026.
Ganor, Y., V.I. Teichberg, and M. Levite. 2007. TCR activation elimi-
nates glutamate receptor GluR3 from the cell surface of normal human 
T cells, via an autocrine/paracrine granzyme B-mediated proteolytic 
cleavage. J. Immunol. 178:683–692.
Ganor, Y., Z. Zhou, D. Tudor, A. Schmitt, M.C. Vacher-Lavenu, L. 
Gibault, N. Thiounn, J. Tomasini, J.P. Wolf, and M. Bomsel. 2010. 
Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but 
not outer, foreskin mucosa and engages Langerhans-T cell conjugates. 
Mucosal Immunol. 3:506–522. http://dx.doi.org/10.1038/mi.2010.32
Ganor, Y., Z. Zhou, J. Bodo, D. Tudor, J. Leibowitch, D. Mathez, A. 
Schmitt, M.C. Vacher-Lavenu, M. Revol, and M. Bomsel. 2013. The 
adult penile urethra is a novel entry site for HIV-1 that preferentially 
targets resident urethral macrophages. Mucosal Immunol. 6:776–786. 
http://dx.doi.org/10.1038/mi.2012.116
Geijtenbeek, T.B., D.S. Kwon, R. Torensma, S.J. van Vliet, G.C. van 
Duijnhoven, J. Middel, I.L. Cornelissen, H.S. Nottet, V.N. KewalRamani, 
D.R. Littman, et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1- 
binding protein that enhances trans-infection of T cells. Cell. 100: 
587–597. http://dx.doi.org/10.1016/S0092-8674(00)80694-7
Geissmann, F., C. Prost, J.P. Monnet, M. Dy, N. Brousse, and O. Hermine. 
1998. Transforming growth factor 1, in the presence of granulo-
cyte/macrophage colony-stimulating factor and interleukin 4, induces 
differentiation of human peripheral blood monocytes into dendritic 
Langerhans cells. J. Exp. Med. 187:961–966. http://dx.doi.org/10.1084/ 
jem.187.6.961
Griffiths, C.E., D. Railan, W.M. Gallatin, and K.D. Cooper. 1995. The 
ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell al-
loantigen presentation to CD4+ T cells. Br. J. Dermatol. 133:823–829. 
http://dx.doi.org/10.1111/j.1365-2133.1995.tb06911.x
Hosoi, J., G.F. Murphy, C.L. Egan, E.A. Lerner, S. Grabbe, A. Asahina, 
and R.D. Granstein. 1993. Regulation of Langerhans cell function by 
nerves containing calcitonin gene-related peptide. Nature. 363:159–163. 
http://dx.doi.org/10.1038/363159a0
Magérus-Chatinet, A., H. Yu, S. Garcia, E. Ducloux, B. Terris, and M. 
Bomsel. 2007. Galactosyl ceramide expressed on dendritic cells can 
mediate HIV-1 transfer from monocyte derived dendritic cells to au-
tologous T cells. Virology. 362:67–74. http://dx.doi.org/10.1016/j.virol 
.2006.11.035
Masterson, A.J., C.C. Sombroek, T.D. De Gruijl, Y.M. Graus, H.J. van der 
Vliet, S.M. Lougheed, A.J. van den Eertwegh, H.M. Pinedo, and R.J. 
Scheper. 2002. MUTZ-3, a human cell line model for the cytokine- 
induced differentiation of dendritic cells from CD34+ precursors. Blood. 
100:701–703. http://dx.doi.org/10.1182/blood.V100.2.701
Mc Dermott, R., U. Ziylan, D. Spehner, H. Bausinger, D. Lipsker, M. 
Mommaas, J.P. Cazenave, G. Raposo, B. Goud, H. de la Salle, et al. 
2002. Birbeck granules are subdomains of endosomal recycling com-
partment in human epidermal Langerhans cells, which form where 
Langerin accumulates. Mol. Biol. Cell. 13:317–335. http://dx.doi.org/ 
10.1091/mbc.01-06-0300
McCarthy, B.G., S.T. Hsieh, A. Stocks, P. Hauer, C. Macko, D.R. 
Cornblath, J.W. Griffin, and J.C. McArthur. 1995. Cutaneous inner-
vation in sensory neuropathies: evaluation by skin biopsy. Neurology. 
45:1848–1855. http://dx.doi.org/10.1212/WNL.45.10.1848
Moreno, M.J., J.A. Terrón, D.B. Stanimirovic, H. Doods, and E. Hamel. 
2002. Characterization of calcitonin gene-related peptide (CGRP) 
receptors and their receptor-activity-modifying proteins (RAMPs) in 
human brain microvascular and astroglial cells in culture. Neuropharmacology. 
42:270–280. http://dx.doi.org/10.1016/S0028-3908(01)00176-9
ethical committee of the San Raffaele Scientific Institute, the Comitato 
Etico dell’Istituto Scientifico Ospedale San Raffaele, approved the investiga-
tions. All human subjects provided informed consents. Animals from which 
blood was sampled were maintained under guidelines established by the Ani-
mal Welfare Act and the NIH Guide for the Care and Use of Laboratory 
Animals, as we described previously (Bomsel et al., 2011).
A total of 38 plasma samples were selected for the study as follows: 
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